Subscribe to Search results

Professor Edward Tuddenham told the Inquiry that inactivation could and should have been achieved earlier.

Published on:

Professor Tuddenham accepted in hindsight that the risk of factor concentrates transmitting blood-borne infections was not sufficiently appreciated.

Published on:

Professor Tuddenham told the Inquiry that DDAVP was not used regularly at the Royal Free until some time after 1980.

Published on:

Professor Tuddenham became aware of the association between people with haemophilia receiving factor concentrates and AIDS.

Published on:

Professor Ian Franklin gave evidence to the Inquiry that Dame Sheila "didn't really know what was going to be happening" when reflecting on the findings in her textbook 'Disease of the Liver and Biliary Systems'.

Published on:

The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply

Published on:

Professor Christine Lee continued her oral evidence to the Inquiry in her second day of testimony. She said that she thought compensation was wrong because it suggested liability and that the idea that any decent person would give someone treatment that they knew would cause harm was ridiculous.

Published on:

Professor Lee confirmed that no changes were made in the Royal Free's treatment policies until heat-treated products became available at the end of 1984

Published on:

Royal Free had a policy of keeping patients on the same batch until it ran out, as recalled by Professor Christine Lee.

Published on:

Professor Lee, expressed the firm view that the Royal Free's haemophilia centre directors could not be criticised for the complete change from cryoprecipitate to concentrate, also citing the convenience and the efficiency as reasons for change.

Published on:

Dr Biggs served as director until 1977 when she was succeeded by Dr Rizza.

Published on:

The haemophilia centre at St Thomas' Hospital was under the directorship of Professor Ingram until 1979, when he was succeeded by Professor Geoffrey Savidge.

Published on:

Dr Anna Pettigrew asserted in her statement to the Inquiry that the patients at Glasgow Yorkhill Haemophilia Centre would be transferred to Glasgow Royal Infirmary at 15-16.

Published on:

Dr Pettigrew noted that the commercial Factor VIII product was more 'user friendly' and dissolved more quickly than the SNBTS product.

Published on:

There was no system of batch dedication, despite their being some evidence of attempts to introduce one towards the end of 1984 or 1985 where there were attempts to introduce one.

Published on:

Dr Willoughby did not attend UKHCDO meetings and Dr Pettigrew asserted that Dr Willoughby did not disseminate UKHCDO material to her and her more junior colleagues at Yorkhill about NANB Hepatitis

Published on:

Dr Pettigrew noted during her hearings at the Inquiry that Dr Willoughby did not have any conversations with her about the risk of NANB Hepatitis and was not aware of NANB as a concept until liver biopsies were carried out on her haemophilia patients in 1984.

Published on:

Dr Pettigrew noted that there was no system from senior doctors of updating junior doctors with updates about medical and clinical developments

Published on:

Dr Pettigrew did not raise or discuss AIDS with Dr Willoughby in 1982 as Dr Pettigrew herself did not become aware of haemophiliacs contracting AIDS until 1983 and Dr Willoughby did not make her aware of this.

Published on:

Dr Pettigrew asserted that there was no steps taken while Dr Willoughby was director to reduce or minimise the risk of patients being infected with Hepatitis or AIDS.

Published on: